• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用8-苯胺基-1-萘磺酸盐探测尿激酶型纤溶酶原激活剂与其受体之间的配体相互作用。仅在完整受体上暴露疏水结合位点的证据。

Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor.

作者信息

Ploug M, Ellis V, Danø K

机构信息

Finsen Laboratory, Rigshospitalet, Copenhagen O, Denmark.

出版信息

Biochemistry. 1994 Aug 2;33(30):8991-7. doi: 10.1021/bi00196a017.

DOI:10.1021/bi00196a017
PMID:8043585
Abstract

The cellular receptor for urokinase-type plasminogen activator (uPAR) is a glycolipid-anchored membrane protein thought to play a primary role in the generation of pericellular proteolytic activity, and to be involved in cancer cell invasion and metastasis. This protein is composed of three homologous domains, the NH2-terminal of which is involved in the high-affinity binding (Kd approximately 0.1-1.0 nM) to the epidermal growth factor-like module of urokinase-type plasminogen activator (uPA). Here we report that intact uPAR binds the low molecular weight fluorophore 8-anilino-1-naphthalenesulfonate (ANS) to form a 1:1 stoichiometric complex and that the resulting enhancement of the ANS fluorescence probes the functional state of uPAR as judged by several independent criteria. First, the uPAR-mediated increase in ANS fluorescence can be titrated by uPA as well as by its receptor binding derivatives (the amino-terminal fragment and the growth factor-like module). Second, an anti-uPAR monoclonal antibody, capable of preventing uPA binding, can also titrate the uPAR-dependent ANS fluorescence whereas other antibodies not interfering with uPA binding are unable to exert this effect. Third, the dissociation profile of uPA-uPAR complexes as a function of increasing concentrations of guanidine hydrochloride closely parallels the loss of the ANS binding site in uPAR. Finally, liberation of the NH2-terminal domain from uPAR by limited chymotrypsin cleavage after Tyr87 leads to a loss of both enhanced ANS fluorescence and high-affinity uPA binding.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

尿激酶型纤溶酶原激活剂(uPAR)的细胞受体是一种糖脂锚定膜蛋白,被认为在细胞周围蛋白水解活性的产生中起主要作用,并参与癌细胞的侵袭和转移。该蛋白由三个同源结构域组成,其氨基末端参与与尿激酶型纤溶酶原激活剂(uPA)的表皮生长因子样模块的高亲和力结合(解离常数约为0.1 - 1.0 nM)。在此我们报告,完整的uPAR与低分子量荧光团8-苯胺基-1-萘磺酸盐(ANS)结合形成1:1化学计量复合物,并且由此产生的ANS荧光增强根据几个独立标准探测了uPAR的功能状态。首先,uPAR介导的ANS荧光增加可被uPA及其受体结合衍生物(氨基末端片段和生长因子样模块)滴定。其次,一种能够阻止uPA结合的抗uPAR单克隆抗体也能滴定uPAR依赖的ANS荧光,而其他不干扰uPA结合的抗体则无法发挥这种作用。第三,uPA - uPAR复合物的解离曲线作为盐酸胍浓度增加的函数与uPAR中ANS结合位点的丧失密切平行。最后,在Tyr87后通过有限的胰凝乳蛋白酶切割从uPAR释放氨基末端结构域导致增强的ANS荧光和高亲和力uPA结合均丧失。(摘要截短至250字)

相似文献

1
Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor.用8-苯胺基-1-萘磺酸盐探测尿激酶型纤溶酶原激活剂与其受体之间的配体相互作用。仅在完整受体上暴露疏水结合位点的证据。
Biochemistry. 1994 Aug 2;33(30):8991-7. doi: 10.1021/bi00196a017.
2
Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane. Evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction.使用四硝基甲烷对尿激酶型纤溶酶原激活剂及其受体进行化学修饰。受体-配体相互作用过程中两个分子中特定酪氨酸残基参与作用的证据。
Biochemistry. 1995 Oct 3;34(39):12524-34. doi: 10.1021/bi00039a006.
3
Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain.尿激酶型纤溶酶原激活剂切割其细胞表面受体,释放出配体结合结构域。
J Biol Chem. 1992 Sep 5;267(25):18224-9.
4
Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation.使用十肽拮抗剂对人尿激酶型纤溶酶原激活剂受体进行光亲和标记。复合配体结合位点和短结构域间间隔的证据。
Biochemistry. 1998 Mar 17;37(11):3612-22. doi: 10.1021/bi972787k.
5
Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding.人尿激酶型纤溶酶原激活剂与其受体的结合:涉及物种特异性和结合的残基。
Arterioscler Thromb Vasc Biol. 1998 May;18(5):693-701. doi: 10.1161/01.atv.18.5.693.
6
Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site.通过对尿激酶型纤溶酶原激活剂受体进行光亲和标记来鉴定参与配体结合的特定位点。位于uPAR结构域I和III中同等位置的残基参与复合配体结合位点的组装。
Biochemistry. 1998 Nov 24;37(47):16494-505. doi: 10.1021/bi981203r.
7
Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).环[19,31][D-半胱氨酸19]-尿激酶型纤溶酶原激活剂19-31是尿激酶型纤溶酶原激活剂与其受体(CD87)相互作用的强效竞争性拮抗剂。
Biol Chem. 2001 Aug;382(8):1197-205. doi: 10.1515/BC.2001.150.
8
Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor.尿激酶 - 纤溶酶原激活物抑制剂1型复合物的内化作用由尿激酶受体介导。
J Biol Chem. 1992 May 5;267(13):9129-33.
9
Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes.玻连蛋白通过捕获可溶性尿激酶受体-尿激酶复合物,将蛋白水解活性集中于细胞表面和细胞外基质。
Blood. 1998 Apr 1;91(7):2305-12.
10
A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor.尿激酶生长因子结构域与2型纤溶酶原激活物抑制剂的杂合蛋白可抑制尿激酶活性,并与尿激酶受体结合。
Eur J Biochem. 1992 Jul 1;207(1):177-83. doi: 10.1111/j.1432-1033.1992.tb17035.x.

引用本文的文献

1
uPAR: An Essential Factor for Tumor Development.尿激酶型纤溶酶原激活物受体:肿瘤发展的关键因素
J Cancer. 2021 Oct 17;12(23):7026-7040. doi: 10.7150/jca.62281. eCollection 2021.
2
Mimicry of the regulatory role of urokinase in lamellipodia formation by introduction of a non-native interdomain disulfide bond in its receptor.引入尿激酶受体中非天然的结构域间二硫键模拟其在片状伪足形成中的调节作用。
J Biol Chem. 2011 Dec 16;286(50):43515-26. doi: 10.1074/jbc.M111.300020. Epub 2011 Oct 24.
3
Molecular imaging of pancreatic cancer in an animal model using targeted multifunctional nanoparticles.
使用靶向多功能纳米颗粒对动物模型中的胰腺癌进行分子成像。
Gastroenterology. 2009 May;136(5):1514-25.e2. doi: 10.1053/j.gastro.2009.01.006. Epub 2009 Jan 14.
4
Urokinase receptor cleavage: a crucial step in fibroblast-to-myofibroblast differentiation.尿激酶受体裂解:成纤维细胞向肌成纤维细胞分化的关键步骤。
Mol Biol Cell. 2007 Jul;18(7):2716-27. doi: 10.1091/mbc.e06-10-0912. Epub 2007 May 16.
5
SPARC-induced migration of glioblastoma cell lines via uPA-uPAR signaling and activation of small GTPase RhoA.SPARC通过uPA-uPAR信号通路诱导胶质母细胞瘤细胞系迁移并激活小GTP酶RhoA。
Int J Oncol. 2006 Dec;29(6):1349-57.
6
Structural analysis and tissue localization of human C4.4A: a protein homologue of the urokinase receptor.人C4.4A的结构分析与组织定位:尿激酶受体的一种蛋白质同源物
Biochem J. 2004 Jun 15;380(Pt 3):845-57. doi: 10.1042/BJ20031478.
7
Dimerization controls the lipid raft partitioning of uPAR/CD87 and regulates its biological functions.二聚化控制尿激酶型纤溶酶原激活物受体(uPAR)/CD87在脂筏中的分布,并调节其生物学功能。
EMBO J. 2003 Nov 17;22(22):5994-6003. doi: 10.1093/emboj/cdg588.
8
The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R.尿激酶的纤维蛋白溶解受体激活G蛋白偶联趋化受体FPRL1/LXA4R。
Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1359-64. doi: 10.1073/pnas.022652999. Epub 2002 Jan 29.
9
Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor.尿激酶催化的尿激酶受体裂解需要完整的糖脂锚。
Biochem J. 2001 Sep 15;358(Pt 3):673-9. doi: 10.1042/0264-6021:3580673.
10
Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin.Rac介导细胞骨架重排以及由尿激酶型纤溶酶原激活物受体与玻连蛋白结合所诱导的细胞运动性增加。
J Cell Biol. 2001 Mar 19;152(6):1145-57. doi: 10.1083/jcb.152.6.1145.